Reconsider SSRIs for depression: study

The SSRI paroxetine offers little benefit over placebo for depression, according to a study of previously unpublished data.

The first analysis of GlaxoSmithKline's entire dataset of published and unpublished trials of paroxetine for depression and anxiety found the SSRI "provides only a modest advantage" compared with placebo.

Placebo conferred almost 80% of the benefit of the active drug, the analysis of 39 double-blind placebo-controlled trials found.